(Q51754423)

11 April 2018

title

An IL-4/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice. (English)

1 reference

11 April 2018

author name string

Marion T Kasaian

1

1 reference

11 April 2018

Kimberly Marquette

2

1 reference

11 April 2018

Susan Fish

3

1 reference

11 April 2018

Charlene DeClercq

4

1 reference

11 April 2018

Rita Agostinelli

5

1 reference

11 April 2018

Timothy A Cook

6

1 reference

11 April 2018

Agnes Brennan

7

1 reference

11 April 2018

Julie Lee

8

1 reference

11 April 2018

Lori Fitz

9

1 reference

11 April 2018

Jonathan Brooks

10

1 reference

11 April 2018

Yulia Vugmeyster

11

1 reference

11 April 2018

Cara M M Williams

12

1 reference

11 April 2018

Alan Lofquist

13

1 reference

11 April 2018

Lioudmila Tchistiakova

14

1 reference

11 April 2018

publication date

1 July 2013

1 reference

11 April 2018

American Journal of Respiratory Cell and Molecular Biology

published in

1 reference

11 April 2018

volume

49

1 reference

11 April 2018

issue

1

1 reference

11 April 2018

page(s)

37-46

1 reference

11 April 2018

The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor

cites work

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Untangling the complex web of IL-4- and IL-13-mediated signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

IL-4 induces IL-13-independent allergic airway inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Comparative roles of IL-4, IL-13, and IL-4Ralpha in dendritic cell maturation and CD4+ Th2 cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

IL-13 receptor α1 differentially regulates aeroallergen-induced lung responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Treatment of cells with n-alpha-tosyl-L-phenylalanine-chloromethyl ketone induces the proteolytic loss of STAT6 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Stat6-protease but not Stat5-protease is inhibited by an elastase inhibitor ONO-5046.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Model systems for investigating mucin gene expression in airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Upregulation of MUC8 and downregulation of MUC5AC by inflammatory mediators in human nasal polyps and cultured nasal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

IL-13 as a therapeutic target for respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Cytokine inhibition in severe asthma: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Anti-interleukin-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

IL-4 and IL-13 dual antagonism: a promising approach to the dilemma of generating effective asthma biotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Dual targeting strategies with bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

On the domain pairing in chimeric antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Characterization of Ascaris-induced biphasic skin allergic reaction model in mice: possible roles of mast cells in early-phase and CD4-positive T cells in late-phase reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Impaired development of Th2 cells in IL-13-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

IL-13 overexpression predisposes to anaphylaxis following antigen sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Neonatal exposure with LPS and/or allergen prevents experimental allergic airways disease: development of tolerance using environmental antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Interleukin-13: central mediator of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

The role of IL-13 in established allergic airway disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Requirement for IL-13 independently of IL-4 in experimental asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

Regulation of IL-13 receptor alpha 1 expression and signaling on human tonsillar B-lymphocyte subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

TNF-alpha potentiates IL-4/IL-13-induced IL-13Ralpha2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1165%2FRCMB.2012-0500OC

21 January 2018

Identifiers

DOI

10.1165/RCMB.2012-0500OC

1 reference

11 April 2018

1 reference

11 April 2018